Share This Page
Drug Price Trends for RYALTRIS
✉ Email this page to a colleague
Average Pharmacy Cost for RYALTRIS
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| RYALTRIS 665-25 MCG SPRAY | 59467-0700-27 | 8.23238 | GM | 2024-12-18 |
| RYALTRIS 665-25 MCG SPRAY | 59467-0700-27 | 8.23640 | GM | 2024-11-20 |
| RYALTRIS 665-25 MCG SPRAY | 59467-0700-27 | 8.23725 | GM | 2024-10-23 |
| RYALTRIS 665-25 MCG SPRAY | 59467-0700-27 | 8.24132 | GM | 2024-09-18 |
| RYALTRIS 665-25 MCG SPRAY | 59467-0700-27 | 8.23043 | GM | 2024-08-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Ryaltris
Introduction to Ryaltris
Ryaltris, a nasal spray developed by Glenmark Pharmaceuticals, is designed for the symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age. The drug combines an antihistamine (olopatadine) and a steroid (mometasone furoate) to alleviate symptoms such as a stuffy nose, runny nose, nasal itching, sneezing, and itchy, red, and watery eyes associated with allergic rhinitis[2][3].
Market Presence and Expansion
As of the latest reports, Ryaltris has been commercialized in 31 global markets and has secured marketing applications in over 70 markets. The product has also received approval in 18 additional markets, where it is set to be launched within the next 3 to 6 months by either Glenmark or its partners[1][2].
Glenmark has also formed strategic partnerships to expand the market reach of Ryaltris. For instance, in January 2022, Glenmark partnered with Lotus Pharmaceutical Co. Ltd. to introduce Ryaltris in Singapore, Hong Kong, and Vietnam, leveraging Lotus's established presence in Southeast Asia[3][4].
Sales Projections
Glenmark Pharmaceuticals is optimistic about the sales performance of Ryaltris, projecting revenues to hit approximately USD 80 million in 2024. This forecast is based on the product's strong initial performance and its potential in untapped major markets like China and Brazil[1][2].
Future Growth Potential
The company anticipates that Ryaltris will be a substantial product over the next five years, with potential peak sales that could capture 15-20% of the market share. This projection underscores the significant growth potential of Ryaltris in the allergic rhinitis drugs market[1][2].
Market Size and Growth of Allergic Rhinitis Drugs
The global allergic rhinitis drugs market is expected to grow steadily, reaching $18.78 billion by 2028 at a compound annual growth rate (CAGR) of 4.6%. This growth is driven by factors such as increasing pollution levels, rising respiratory disorders, changing climatic conditions, and a growing number of individuals suffering from allergies[3].
Regional Market Analysis
The Asia-Pacific region was the largest in the allergic rhinitis drugs market in 2023, with other significant regions including Western Europe, Eastern Europe, North America, and South America. The growth in these regions is fueled by technological developments in treatment methods, the development of new antihistamines, and advancements in allergy diagnostics and treatments[3].
Pricing and Cost Considerations
The average retail price for Ryaltris is approximately $330.38 per 29GM of 665-25MCG/ACT Spray Btl. However, prices can vary depending on the pharmacy and the use of discount coupons or generic versions. For example, using a SingleCare coupon can reduce the cost to around $251.71 for the generic version, Olopatadine HCl-Mometasone Furoate[5].
Cost Savings Strategies
Patients can reduce their out-of-pocket costs by opting for the generic version of Ryaltris or using discount coupons. Here is a comparison of prices at different pharmacies:
| Pharmacy | Ryaltris Retail Price | Ryaltris SingleCare Price |
|---|---|---|
| CVS Pharmacy | $296.96 | $259.91 |
| Walmart | $298.70 | $267.38 |
| Walgreens | $298.12 | $266.22 |
| Kroger Pharmacy | $298.99 | $257.74 |
| Albertsons Pharmacy | $303.77 | $265.35 |
| Rite Aid Pharmacy | $334.95 | $263.90 |
These prices highlight the potential for cost savings through the use of coupons and generic alternatives[5].
Competitive Landscape
The market for allergic rhinitis drugs is competitive, with several major players including Teva Pharmaceuticals, Hikma Pharmaceuticals PLC, and Glenmark Pharmaceuticals. Partnerships and collaborations among these companies are common, as seen in Glenmark's licensing agreement with Hikma Pharmaceuticals PLC to commercialize Ryaltris in the U.S.[4].
Technological and Regulatory Trends
Technological advancements in treatment methods and diagnostics are driving growth in the allergic rhinitis drugs market. For instance, new antihistamines and advancements in allergy treatment are expected to play a significant role in the market's future growth. Regulatory approvals and compliance are also crucial for the successful launch and commercialization of products like Ryaltris[3].
Conclusion
Ryaltris is poised to be a significant player in the allergic rhinitis drugs market, with strong sales projections and a robust expansion strategy. The product's effectiveness in alleviating symptoms of allergic rhinitis, coupled with its growing market presence and strategic partnerships, positions it for substantial growth over the next few years.
Key Takeaways
- Sales Projections: Ryaltris is expected to generate approximately USD 80 million in sales in 2024.
- Market Expansion: The product has been commercialized in 31 markets and has approvals in 18 additional markets.
- Growth Potential: Ryaltris could capture 15-20% of the market share over the next five years.
- Pricing: The average retail price is around $330, but costs can be reduced with coupons and generic versions.
- Market Size: The global allergic rhinitis drugs market is expected to reach $18.78 billion by 2028.
- Competitive Landscape: The market is competitive, with major players forming partnerships and collaborations.
FAQs
Q: What is Ryaltris used for? A: Ryaltris is used for the symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children over 12 years of age.
Q: How much is Ryaltris expected to generate in sales in 2024? A: Ryaltris is expected to generate approximately USD 80 million in sales in 2024.
Q: In how many markets has Ryaltris been commercialized? A: Ryaltris has been commercialized in 31 global markets.
Q: What are the key factors driving the growth of the allergic rhinitis drugs market? A: The growth is driven by increasing pollution levels, rising respiratory disorders, changing climatic conditions, and a growing number of individuals suffering from allergies.
Q: How can patients reduce the cost of Ryaltris? A: Patients can reduce the cost by using discount coupons or opting for the generic version, Olopatadine HCl-Mometasone Furoate.
Sources
- Business Standard: "Glenmark Pharma eyes $80 mn from it's nasal spray Ryaltris sales next year"[1]
- BW Healthcare World: "Glenmark Pharmaceuticals Forecasts Ryaltris Nasal Spray Sales To Reach USD 80 Million In 2024"[2]
- The Business Research Company: "Global Allergic Rhinitis Drugs Market Report 2024"[3]
- BioSpace: "Inhalation And Nasal Spray Generic Drugs Market Size To Surpass US$ 38.45 Bn By 2030"[4]
- SingleCare: "Ryaltris Coupons & Prices"[5]
More… ↓
